Wednesday, November 15, 2017 6:35:33 PM
Word, I still own a not insignificant quantity of BPTH shares (although it becomes less significant with every recent management decision). I have held my position for in excess of 5 years now having purchased shares at a variety of prices from $0.30 to just short of $5 pps. I feel a responsibility, as a shareholder, to not only get this technology to the market but to hold the management team accountable for their performance or lack of performance. I believe that once the therapy is available to treat the various targeted cancers the share price will not be an issue. Right now,IMO, we do not have the correct management to make that happen quickly and efficiently.
Recent BPTH News
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 07/11/2025 08:44:58 PM
- Life Sciences Investor Forum: Now Available for Online Viewing • GlobeNewswire Inc. • 06/13/2025 12:35:00 PM
- Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum • GlobeNewswire Inc. • 06/09/2025 11:00:00 AM
- Bio-Path Holdings Provides Clinical and Operational Update • GlobeNewswire Inc. • 06/03/2025 11:00:00 AM
- Form 253G3 - • Edgar (US Regulatory) • 06/02/2025 08:35:21 PM
